Effect of acute and chronic administration of the GABA[sub B] agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease

Ciccaglione, A.F.; Marzio, L.
April 2003
Gut;Apr2003, Vol. 52 Issue 4, p464
Academic Journal
Background and aims: The γ-aminobutyric acid (GABA[sub B]) agonist baclofen has been shown to reduce reflux episodes during the first three postprandial hours in patients with gastro-oesophageal reflux disease (GORD) and in normal controls. The aim of the study was to assess the effect of acute (one day) and chronic (four weeks) administration of baclofen on 24 hour pH merry and symptoms in GORD patients and normal controls. Patients and methods: Acute study: 28 patients with GORD with none or mild oesophagitis at endoscopy and 15 controls underwent oesophageal and gastric 48 hour pH metry in which baclofen or placebo was given for 24 hours in a double blinded manner. Chronic study: 16 GORD patients received baclofen (10 mg four times daily) or placebo for four weeks. Twenty four hour oesophageal pH metry and reflux symptom scores were evaluated before and at the end of treatment. Results: Acute study: the number of reflux episodes and per cent time with pH <4 was significantly lower after baclofen in GORD patients and controls (p<0.003; p<0.0007). Gastric pH increased significantly in GORD patients and controls (p<0.001; p<0.05). Chronic study: four weeks after initial administration of baclofen, the number of reflux episodes and percentage of time with pH <4 significantly decreased in all GORD patients (p<0.003; p<0.02). Symptom scores significantly improved after treatment with baclofen (p<0.0007). Conclusions: The GABA[sub B] agonist baclofen reduces 24 hour gastro-oesophageal reflux and increases gastric pH in GORD patients and controls. When given for one month to GORD patients, baclofen reduces oesophageal acid refluxes and significantly improves symptoms. Baclofen may be useful in the therapy of GORD.


Related Articles

  • Failure of reflux inhibitors in clinical trials: bad drugs or wrong patients? Kahrilas, Peter J.; Boeckxstaens, Guy // Postgraduate Medical Journal;Feb2013, Vol. 89 Issue 1048, p111 

    Treatment modalities for gastro-oesophageal reflux disease (GORD) mirror the pathophysiology of the disease. Since acid plays a key role in GORD-associated mucosal lesions, proton pump inhibitors (PPIs) are the dominant GORD treatment, being the most potent inhibitors of acid secretion...

  • Patients who take antacids regularly may have more than chronic heartburn.  // Modern Medicine;Aug95, Vol. 63 Issue 8, p13 

    Reports that patients with chronic heartburn who take antacids may be suffering from gastroesophageal reflux according to Seymour Sabesin. Symptoms of gastroesophageal reflux; Treatment and prevention.

  • New proton-pump inhibitor heals resistant erosive esophagitis.  // Modern Medicine;Aug95, Vol. 63 Issue 8, p46 

    Presents an abstract of the study titled `Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy: Lansoprazole, a new proton pump inhibitor,' by M. Robinson, D.R. Campbell, et al, published in the March 1995 issue of `D ig. Dis. Sci.'

  • New reflux guidelines seek to avoid the under-treatment of patients.  // Modern Medicine;Jan96, Vol. 64 Issue 1, p11 

    Presents the findings of a research published in the November 13, 1995 issue of the `Archives of Internal Medicine' journal on the inappropriate or inadequate drug therapies administered to most gastroesophageal reflux disease patients. Mistake in H2 blocker prescription; Recommendations for...

  • The most effective treatment may not be the most practical for esophagitis.  // Modern Medicine;Jan96, Vol. 64 Issue 1, p20 

    Reports on findings published in the October 1995 issue of `The New Journals of Medicine' on the most effective treatment of reflux esophagitis. Proton-pump inhibitor omeprazole and cisapride combination's effectiveness; Description of the study group; Rate of recurrence; Side effects;...

  • Take another look at surgery for chronic reflux; a new method has shorter recovery time and is...  // Modern Medicine;Jun96, Vol. 64 Issue 6, p6 

    Reports on a surgical method in the therapy for gastroesophageal reflux, a condition characterized by the chronic exit of food from the stomach to the esophagus causing ulcerations in the mucus of the esophageal tract. Use of laparoscopic methods; Recovery time; Prevention of gas-bloat syndrome;...

  • Fundoplication versus medication for GERD. Diloreto, Stacy // Patient Care;7/30/2001, Vol. 35 Issue 14, p56 

    Reports on a study that did a randomized controlled trial of fundoplication in the treatment of gastroesophageal reflux disease. Comparison of the surgical procedure with pharmacologic therapy; Disadvantage of surgery.

  • Acid inhibitor is safe, effective for refractory reflux esophagitis.  // Geriatrics;Jan95, Vol. 50 Issue 1, p59 

    Presents an abstract on the use of acid inhibitor omeprazole in treating gastroesophageal reflux published in the periodical `Annals of Internal Medicine,' by E.C. Klinkenberg-Knol, H.P.M. Festen and J.B. Jansen. Healing assessment in experimental patients; Esophagitis recurrence in patients...

  • Literature reviews. T.E.L.; Lampe, John B. // Clinical Pediatrics;Mar1995, Vol. 34 Issue 3, p170 

    Reviews the article `Fundoplication in 160 children under 2 years of age,' by N.I. Kazerooni, J. VanCamp and R.B. Hirschl published in the periodical `Journal of Pediatric Surgery,' dated 1994.


Read the Article


Sign out of this library

Other Topics